Gregory A Joice1, Steven P Rowe, Kenneth J Pienta, Michael A Gorin. 1. aThe James Buchanan Brady Urological Institute and Department of Urology bThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: The aim of this review is to discuss how novel imaging modalities and molecular markers are shaping the definition of oligometastatic prostate cancer. RECENT FINDINGS: To effectively classify a patient as having oligometastatic prostate cancer, diagnostic tests must be sensitive enough to detect subtle sites of metastatic disease. Conventional imaging modalities can readily detect widespread polymetastatic disease but do not have the sensitivity necessary to reliably classify patients as oligometastatic. Molecular imaging using both metabolic- and molecularly-targeted radiotracers has demonstrated great promise in aiding in our ability to define the oligometastatic state. Perhaps the most promising data to date have been generated with radiotracers targeting prostate-specific membrane antigen. In addition, early studies are beginning to define biologic markers in the oligometastatic state that may be indicative of disease with minimal metastatic potential. SUMMARY: Recent developments in molecular imaging have allowed for improved detection of metastatic prostate cancer allowing for more accurate staging of patients with oligometastatic disease. Future development of biologic markers may assist in defining the oligometastatic state and determining prognosis.
PURPOSE OF REVIEW: The aim of this review is to discuss how novel imaging modalities and molecular markers are shaping the definition of oligometastatic prostate cancer. RECENT FINDINGS: To effectively classify a patient as having oligometastatic prostate cancer, diagnostic tests must be sensitive enough to detect subtle sites of metastatic disease. Conventional imaging modalities can readily detect widespread polymetastatic disease but do not have the sensitivity necessary to reliably classify patients as oligometastatic. Molecular imaging using both metabolic- and molecularly-targeted radiotracers has demonstrated great promise in aiding in our ability to define the oligometastatic state. Perhaps the most promising data to date have been generated with radiotracers targeting prostate-specific membrane antigen. In addition, early studies are beginning to define biologic markers in the oligometastatic state that may be indicative of disease with minimal metastatic potential. SUMMARY: Recent developments in molecular imaging have allowed for improved detection of metastatic prostate cancer allowing for more accurate staging of patients with oligometastatic disease. Future development of biologic markers may assist in defining the oligometastatic state and determining prognosis.
Authors: Bert Dhondt; Elise De Bleser; Tom Claeys; Sarah Buelens; Nicolaas Lumen; Jo Vandesompele; Anneleen Beckers; Valerie Fonteyne; Kim Van der Eecken; Aurélie De Bruycker; Jérôme Paul; Pierre Gramme; Piet Ost Journal: World J Urol Date: 2018-12-21 Impact factor: 4.226
Authors: Igor Tsaur; Roman A Blaheta; Robert Dotzauer; Cristian Mirvald; Jonathan Olivier; Cristian Surcel; Maximilian P Brandt; Giorgio Gandaglia; Ioanel Sinescu Journal: World J Urol Date: 2022-10-02 Impact factor: 3.661
Authors: Jurgen J Futterer; Cristian Surcel; Roderick van den Bergh; Hendrik Borgmann; Alberto Briganti; Giorgio Gandaglia; Alexander Kretschmer; Piet Ost; Prasanna Sooriakumaran; Derya Tilki; Massimo Valerio; Guillaume Ploussard; Pieter J L De Visschere; Igor Tsaur Journal: World J Urol Date: 2018-08-01 Impact factor: 4.226